Objective: Increased peripheral metabolism of cortisol may explain compensatory ACTH-dependent adrenal steroidogenesis and hence hyperandrogenism in polycystic ovary syndrome (PCOS). Previous studies have described an increased 5α α-reduction of cortisol or impaired regeneration of cortisol by 11β-HSD1 in PCOS. However, these observations may be confounded by obesity. Moreover, the relationship between alterations in cortisol metabolism and the extent of adrenal androgen hyper-secretion in response to ACTH has not been established. This study aimed to examine the association between cortisol metabolism and ACTH-dependent adrenal hyperandrogenism in PCOS, independently of obesity. Design: We compared 90 PCOS women (age 18-45 yr) stratified by adrenal androgen responses to ACTH 1-24 and 45 controls matched for age and body weight. Methods: PCOS women were stratified as normal responders (NR), intermediate responders (IR), and high responders (HR) to 250 μg ACTH 1-24 : NR (no.=27) had androstenedione and DHEA responses within 2 SD of the mean in controls; IR (no.=43) had DHEA responses >2 SD above controls; HR (no.=20) had both androstenedione and DHEA responses >2 SD above controls. Results: All groups were similar for age, body weight, and body fat distribution. Basal testosterone, androstenedione, and 5α-dihydrotestosterone plasma levels were similarly elevated among the 3 groups of PCOS compared with controls, whereas basal DHEA-S was higher in HR (2.8±1.2 μg/ml) and IR (2.4±1.1 μg/ml) than in NR (1.8±0.8 μg/ml) and controls (1.7±0.6 μg/ml). The HR group had the lowest basal plasma cortisol levels (101±36 ng/ml vs IR 135±42 ng/ml, NR 144±48 ng/ml, and controls 165±48 ng/ml; all p<0.01), but the greatest cortisol response to ACTH 1-24 (Δ (60-0) cortisol 173±60 ng/ml vs IR 136±51 ng/ml, NR 114±50 ng/ml, and controls 127±50 ng/ml; all p<0.01), and the highest urinary excretion of total and 5β-reduced cortisol metabolites (eg 5β-tetrahydrocortisol/cortisol ratio 25.2±15.3 vs IR 18.8±10.7, NR 19.7±11.4, and controls 17.2±13.7; all p<0.05). There were no differences in urinary excretion of 5α-reduced cortisol metabolites or in 5α-dihydrotestosterone/testosterone ratio between groups. Conclusions: Adrenal androgen excess in PCOS is associated with increased inactivation of cortisol by 5β-reductase that may lower cortisol blood levels and stimulate ACTH-dependent steroidogenesis. (J. Endocrinol. Invest. 32: 210-218, 2009) 
INTRODUCTION
The polycystic ovary syndrome (PCOS) affects between 5-7% of women. Although the ovary is the principal source of androgen excess in most of these patients, between 40-70% also demonstrate elevated circulating levels of adrenal androgens, particularly DHEA-S (1-3). The mechanism of adrenal androgen excess in these patients remains poorly understood. One hypothesis is that adrenal hyperandrogenism in PCOS arises from an exaggerated secretory response of the adrenal cortex to ACTH (4). This theory is supported by the close correlation between the responsiveness of adrenal androgens (i.e. androstenedione and DHEA) to ACTH and circulating DHEA-S levels (4). The mechanism leading to the increased responsiveness to ACTH for androstenedione and DHEA in PCOS remains to be determined. It has been postulated that this condition may be secondary to a compensatory overactivation of the hypothalamic-pituitary-adrenal (HPA) axis in response to increased metabolic clearance of cortisol. Similarly to what has been suggested in simple obesity (5), in PCOS increased cortisol metabolism might increase corticotropin releasing factor (CRF) and ACTH secretion by decreasing the HPA axis negative feedback signal, thus maintaining normal cortisol levels at the expense of increased ACTH-dependent steroidogenesis, and therefore of adrenal hyperandrogenism. Most metabolism of cortisol in humans is by enzymes in the liver (A-ring reductases) and kidney [11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)]. The metabolic clearance rate of cortisol is also influenced by the extent of regeneration of cortisol from inactive cortisone, by 11β-HSD1, mainly in the liver (6). A-ring reductases catalyse 5α-or 5β-reduction of several steroids, converting cortisol to inactive metabolites and testosterone to 5α-or 5β-dihydrotestosterone (DHT). 5β-DHT is inactive, but its 5α-isomer (5α-DHT) is the most potent natural androgen. In humans, two isoenzymes of 5α-reductase are encoded by separate genes. 5α-reductase type 1 enzyme is found in non-genital skin, liver, brain, muscle and to a lesser extent in stromal cells of Increased clearance of cortisol by 5β β-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome A. Gambineri 1 , G. Forlani 1 , A. Munarini 1 , F. Tomassoni 1 , G.E. Cognigni 2 , W. Ciampaglia 2 , U. Pagotto 1 , B.R. Walker 3 , and R. Pasquali 1 adipose tissue. 5α-teductase type 2 is predominantly expressed in male accessory reproductive structures, such as the prostate, epididymis and seminal vesicles, and genital skin (7). 5β-reductase is expressed mainly in liver and at lower levels in testis and colon (8).
In cohorts of patients with PCOS, lower ratios of cortisol/cortisone metabolites (9) or higher 5α-reduced cortisol metabolites (10-12) in urine have been reported, suggesting reduced 11β-HSD1 activity (9), or increased 5α-reductase activity (10-12), respectively. However, these results may be confounded by co-existent obesity, since obesity in men and women is associated with impaired liver 11β-HSD1 activity (13, 14) and increased urinary excretion of A-ring reduced cortisol metabolites, particularly 5α-reduced metabolites (15). Moreover, the relationship between alterations in cortisol metabolism and the extent of adrenal androgen hyper-secretion or increased responsiveness to ACTH has not been established. The aim of the present study was to characterize whether exaggerated adrenal androgen responses to exogenous ACTH in PCOS are related to altered peripheral cortisol metabolism, independently of obesity. To achieve this, we stratified PCOS patients according to androstenedione and DHEA response to ACTH.
MATERIALS AND METHODS Subjects
We investigated 90 unmedicated women with PCOS, aged 18-45 yr, and 45 controls recruited from the general population and comparable for age and weight. PCOS women had at least two of: (i) chronic oligo-anovulation [luteal serum progesterone below 2 ng/ml (16)]; (ii) hirsutism [Ferriman-Gallwey score ≥8 (17) or elevated serum total and free testosterone levels (18)]; (iii) polycystic ovarian morphology at ultrasound, according to the Rotterdam consensus conference criteria (19) . Hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, and androgen secreting tumors were excluded by laboratory analysis (20) . Controls had normal ovaries by ultrasound, no signs of hyperandrogenism and regular ovulatory mentrual cycles [progesterone levels ≥8 ng/mL during the luteal phase (16)]. Women were classified as normal-weight if body mass index values (BMI) was >18 kg/m 2 and ≤25 kg/m 2 , overweight if BMI was >25 kg/m 2 and ≤30 kg/m 2 and obese if BMI was >30 kg/m 2 (21). Twenty-eight (31%) PCOS were normal-weight, 10 (11%) were overweight, and 52 (58%) were obese. Within controls, 15 (33%) were normal-weight, 5 (11%) were overweight, and 25 (56%) were obese. None of the subjects included in the study had thyroid dysfunction, abnormal PRL levels, cardiovascular, renal or liver diseases on clinical examination and routine laboratory findings. The protocol was approved by the local Ethics Committee and written informed consent was obtained.
